Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5745827 | 0.98 | KDM4E (0.39) | CYP3A4ALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL676864 | 0.94 | KDM4E (0.41) | CYP3A4ALDH1A1HPGDHSD17B10TSHR | |
| Hydrochloric Acid SCHEMBL5746772 | 0.92 | MAPT (0.40) | CYP3A4ALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL13967975 | 0.87 | SIGMAR1 (0.45) | CYP3A4ALDH1A1HPGDHSD17B10CYP1A2 | |
| SCHEMBL13967926 | 0.87 | KDM4E (0.34) | CYP3A4ALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL13967982 | 0.86 | KDM4E (0.33) | KDM4EGAAMAPTSIGMAR1 | |
| SCHEMBL13967904 | 0.81 | KDM4E (0.32) | KDM4EGAAMAPTSIGMAR1 | |
| SCHEMBL16376115 | 0.81 | HTR2A (0.34) | KDM4EGAAMAPTSIGMAR1HTR2A | |
| SCHEMBL13967928 | 0.81 | KDM4E (0.32) | KDM4EGAAMAPTSIGMAR1 | |
| SCHEMBL13967970 | 0.80 | SIGMAR1 (0.33) | ALDH1A1HPGDHSD17B10KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060269498-A1 | Hair shaping composition comprising at least one polyguanidine other than hydroxide | L'OREAL S.A. (FR) | 2006-11-30 | — | — | US | claimed |
| EP-1487449-A4 | TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS | KING PHARMACEUTICALS RES & DEV (US) | 2006-08-23 | — | — | EP | claimed |
| US-7094895-B2 | Tyrosyl derivatives and their use as P2X7 receptor modulators | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2006-08-22 | — | — | US | claimed |
| EP-1487449-A1 | TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS | King Pharmaceuticals Research and Development Inc. (US) | 2004-12-22 | — | — | EP | claimed |
| US-20030181452-A1 | Tyrosyl derivatives and their use as P2X7 receptor modulators | CREDIT SUISSE AG | 2003-09-25 | — | — | US | claimed |
| WO-2003059353-A1 | TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| US-20120295148-A1 | ELECTROLYTIC SOLUTION FOR SECONDARY BATTERY, SECONDARY BATTERY, ELECTRONIC APPLIANCE, POWER TOOL, ELECTRIC VEHICLE, AND ELECTRIC POWER STORAGE SYSTEM | SONY CORPORATION (JP) | 2012-11-22 | — | — | US | disclosed |
| US-20120295148-A1 | ELECTROLYTIC SOLUTION FOR SECONDARY BATTERY, SECONDARY BATTERY, ELECTRONIC APPLIANCE, POWER TOOL, ELECTRIC VEHICLE, AND ELECTRIC POWER STORAGE SYSTEM | SONY CORPORATION (JP) | 2012-11-22 | — | — | US | disclosed |
| US-20060269498-A1 | Hair shaping composition comprising at least one polyguanidine other than hydroxide | L'OREAL S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
| EP-1723946-A1 | Composition for straightening the hair comprising at least one multi-guanidine not being a hydroxide | L'OREAL (FR) | 2006-11-22 | — | — | EP | disclosed |
| EP-1723947-A1 | Hair waving composition comprising at least a multiguanidine | L'OREAL (FR) | 2006-11-22 | — | — | EP | disclosed |
| EP-1487449-A4 | TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS | KING PHARMACEUTICALS RES & DEV (US) | 2006-08-23 | — | — | EP | disclosed |
| US-7094895-B2 | Tyrosyl derivatives and their use as P2X7 receptor modulators | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1487449-A1 | TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS | King Pharmaceuticals Research and Development Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20030181452-A1 | Tyrosyl derivatives and their use as P2X7 receptor modulators | CREDIT SUISSE AG | 2003-09-25 | — | — | US | disclosed |
| WO-2003059353-A1 | TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060269498-A1 | Hair shaping composition comprising at least one polyguanidine other than hydroxide | KRT18, PLOD3, PRKDC | CYP3A4 4581/4885ALDH1A1 1999/4885HPGD 1380/4885 |
| US-20030181452-A1 | Tyrosyl derivatives and their use as P2X7 receptor modulators | P2RX7, P2RX3, P2RX5 | CYP3A4 934/4885ALDH1A1 2288/4885HPGD 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.